Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Published: 2026-05-11 15:20:29 ET ACTU

Published on 05/11/2026 at 03:20 pm EDT